WeiMai Files Updated Prospectus for Hong Kong IPO, Targets AI Healthcare Leadership

WeiMai filed an updated prospectus for a Hong Kong main board IPO, with China Merchants Securities International as the sole sponsor.

The company said its AI disease-management business delivered stronger revenue growth, narrower losses, and positive adjusted EBITDA in 2025.

Gross margins improved, while the platform expanded to 188 hospital partners and more than 540,000 patients served.

The filing highlights WeiMai’s push toward a Hong Kong listing alongside a clearer path to profitability in AI healthcare.